Physician profile
Robert Keith Stevens
NPI 1689659294
$4,609.74
in general payments reported to CMS, 2019-2025
21 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $385 · 2021: $681 · 2022: $800 · 2023: $569 · 2024: $593 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $764.05 | 2019-2025 | Rocklatan, Tryptyr, Clareon |
| Allergan, INC. | $722.49 | 2019-2022 | |
| Abbvie INC. | $539.90 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Novartis Pharmaceuticals Corporation | $361.06 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $350.03 | 2019 | |
| Oyster Point Pharma, INC. | $337.63 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $268.02 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $258.87 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $251.07 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Baxter Healthcare | $162.86 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $160.33 | 2022 | |
| Ivantis, INC | $150.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $54.78 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $49.88 | 2019-2020 | |
| Shire North American Group INC | $40.24 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $32.64 | 2019-2020 | |
| Harrow Eye, LLC | $30.30 | 2024-2025 | Vevye |
| Rxsight INC | $19.99 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Rochester Medical Corporation | $19.65 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.11 | 2025 | Acthar |
| Ocular Therapeutix, INC. | $17.84 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.